Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC) Meeting Abstract
| Authors: | Chan, S. L.; Sangro, B.; Kelley, R. K.; Lau, G.; Kudo, M.; Sukeepaisarnjaroen, W.; De Toni, E. N.; Furuse, J.; Kang, Y. K.; Galle, P. R.; Rimassa, L.; Heurgue, A.; Tam, V. C.; Dao, T. V.; Chiradoni Thungappa, S.; Breder, V.; Ostapenko, Y. V.; Reig Monzon, M. E.; Gupta, C.; Abou-Alfa, G. K. |
| Abstract Title: | Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC) |
| Meeting Title: | ESMO Asia Congress 2023 |
| Journal Title: | Annals of Oncology |
| Volume: | 34 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2023 Dec 1-3 |
| Meeting Location: | Singapore |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2023-11-01 |
| Start Page: | S1530 |
| End Page: | S1531 |
| Language: | English |
| ACCESSION: | WOS:001122475400150 |
| DOI: | 10.1016/j.annonc.2023.10.282 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 147P -- Source: Wos |
